Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

China Isotope & Radiation Corporation Signs Commercial Deal for Pluvicto, China’s First PSMA Radioligand Therapy

Fineline Cube Jan 22, 2026
Company Deals

Matwings Technology Partners with Leading US Biotech on AIACCLBIO Platform for Biopharmaceutical Pipeline

Fineline Cube Jan 22, 2026
Company Deals

AmCellGene Licenses Mesenchymal Stem Cell Therapy for ACLF to Advanced Regeneration in First Chinese Stem Cell Outbound Deal

Fineline Cube Jan 22, 2026
Company Deals

Huadong Medicine Secures Exclusive China Commercialization Rights for Linaprazan Glurate P‑CAB from Sinorda

Fineline Cube Jan 22, 2026
Company Deals

Novavax Licenses Matrix-M Adjuvant to Pfizer in $530M Deal

Fineline Cube Jan 22, 2026
Company Drug Policy / Regulatory

Merson’s Bemejing Wins First CNMR “Overseas Version” Drug Price Certificate

Fineline Cube Jan 21, 2026
Company Drug

Enhertu Wins China NMPA Approval for Second‑Line HER2‑Positive Gastric Cancer

Fineline Cube Jan 22, 2026
Company Drug

AstraZeneca’s Imfinzi Wins China Approval for Endometrial Cancer, Securing Seventh Indication

Fineline Cube Jan 22, 2026
Company Drug

Ascentage Pharma’s Lisaftoclax (APG-2575) Gets FDA Green Light for Phase III Study

Fineline Cube Aug 7, 2023

China-based Ascentage Pharma (HKG: 6855) has announced that it has received approval from the US...

Company Medical Device

Jenscare Scientific and Lifetech Scientific Achieve Milestone with First Compassionate Use of LuX-Valve Plus

Fineline Cube Aug 7, 2023

Partners Jenscare Scientific Co., Ltd. (HKG: 9877), a leading structural heart disease device manufacturer based...

Policy / Regulatory

GuangDong Pharmaceutical Association Releases Updated Off-Label Drug List for 2023

Fineline Cube Aug 7, 2023

The GuangDong Pharmaceutical Association has released the 2023 version of its off-label drug list, marking...

Company Medical Device

Venus Medtech Receives FDA IDE Approval for VenusP-Valve, a Milestone for Chinese Heart Valve Technology

Fineline Cube Aug 7, 2023

Venus Medtech (Hangzhou) Inc. (HKG: 2500) has announced obtaining Investigational Device Exemption (IDE) approval from...

Company Medical Device

MicroPort CardioFlow Announces Positive Results for Transcatheter Mitral Valve Replacement System

Fineline Cube Aug 7, 2023

China-based MicroPort Scientific Corp’s spin-off, MicroPort CardioFlow Medtech Co., Ltd (HKG: 2160), has announced positive...

Company Deals

Hansoh Pharmaceutical Regains Rights to Ameile After EQRx Partnership Cancellation

Fineline Cube Aug 7, 2023

Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) has announced the cancellation of its partnership and...

Company Deals

Jumpcan Pharmaceutical Partners with Nanjing Zenshine for Exclusive Promotion Rights of ZX-7101A in China

Fineline Cube Aug 7, 2023

China-based Jumpcan Pharmaceutical (SHA: 600566) has announced a strategic partnership with fellow Chinese firm Nanjing...

Company

Gilead Sciences Inc. Reports 5% YOY Revenue Increase in Q2 2023 Financials

Fineline Cube Aug 4, 2023

US-based pharmaceutical major Gilead Sciences Inc., (NASDAQ: GILD) has released its financial results for the...

Company Legal / IP

Amgen Inc. Reports 7% YOY Revenue Increase in Q2 2023 Financials

Fineline Cube Aug 4, 2023

US-based biotechnology company Amgen Inc., (NASDAQ: AMGN) has released its financial results for the second...

Company Legal / IP

GSK Files Patent Infringement Lawsuit Against Pfizer’s RSV Vaccine Abrysvo

Fineline Cube Aug 4, 2023

UK pharmaceutical giant GlaxoSmithKline (NYSE: GSK) has taken US-based Pfizer Inc., (NYSE: PFE) to court,...

Company Deals

Novartis AG and Ionis Pharmaceuticals Renew Collaboration on Lp(a)-Driven CVD Drug

Fineline Cube Aug 4, 2023

Swiss pharmaceutical giant Novartis AG (NYSE: NVS) has returned to US-based Ionis Pharmaceuticals Inc., (NASDAQ:...

Company Drug

Grand Pharmaceutical Group Gets NMPA Approval for Generic Eplerenone for Hypertension

Fineline Cube Aug 4, 2023

China-based Grand Pharmaceutical Group Limited (HKG: 0512) has announced that it has received marketing approval...

Company Deals

Chia Tai Tianqing Secures Exclusive Rights to InventisBio’s D-1553 in China Licensing Deal

Fineline Cube Aug 4, 2023

China-based Chia Tai Tianqing has signed a licensing agreement with compatriot firm InventisBio, securing exclusive...

Company Medical Device

DaVinci Single Port System Launches in Hainan with Successful Surgeries

Fineline Cube Aug 4, 2023

The DaVinci Single Port robot-assisted surgical system technology has been successfully implemented in Boao, Hainan...

Policy / Regulatory

Shanghai’s SMPA Reduces Ceiling Price for Non-Winning Bids in Artificial Joint VBP Tender

Fineline Cube Aug 4, 2023

Shanghai’s Sunshine Medical Procurement All-in-One (SMPA) has issued a notification regarding an artificial joint volume-based...

Company Deals

Kunshan Yiyuan Medical Technology Secures Over RMB 100 Million in Series B Financing

Fineline Cube Aug 4, 2023

Kunshan Yiyuan Medical Technology Co., Ltd (Medical Source), a company in China that specializes in...

Company Deals

HuidaGene Strikes Licensing Deal with Kactus Biosystems for Gene Editing Enzyme hfCas12Max

Fineline Cube Aug 4, 2023

China-based HuidaGene (Shanghai) Biotechnology Co., Ltd has announced a licensing agreement with fellow Shanghai-based firm...

Company

Novartis China’s Business Growth Lead Zhu Jiakang Departs for Personal Reasons

Fineline Cube Aug 4, 2023

Swiss pharmaceutical giant Novartis (NYSE: NVS) has seen the departure of Zhu Jiakang, who led...

Company

BeiGene’s Q2 2023 Financial Report Highlights 81.8% YOY Product Revenue Growth

Fineline Cube Aug 3, 2023

China-based biotech company BeiGene (SHA: 688235, HKG: 6160, NASDAQ: BGNE) has released its financial report...

Legal / IP Policy / Regulatory

National Health Commission’s Anti-Corruption Drive Impacts China’s Pharmaceutical Sector

Fineline Cube Aug 3, 2023

An anti-corruption crackdown announced by the National Health Commission (NHC) at the end of July...

Posts pagination

1 … 439 440 441 … 613

Recent updates

  • China Isotope & Radiation Corporation Signs Commercial Deal for Pluvicto, China’s First PSMA Radioligand Therapy
  • Matwings Technology Partners with Leading US Biotech on AIACCLBIO Platform for Biopharmaceutical Pipeline
  • AmCellGene Licenses Mesenchymal Stem Cell Therapy for ACLF to Advanced Regeneration in First Chinese Stem Cell Outbound Deal
  • Huadong Medicine Secures Exclusive China Commercialization Rights for Linaprazan Glurate P‑CAB from Sinorda
  • Enhertu Wins China NMPA Approval for Second‑Line HER2‑Positive Gastric Cancer
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

China Isotope & Radiation Corporation Signs Commercial Deal for Pluvicto, China’s First PSMA Radioligand Therapy

Company Deals

Matwings Technology Partners with Leading US Biotech on AIACCLBIO Platform for Biopharmaceutical Pipeline

Company Deals

AmCellGene Licenses Mesenchymal Stem Cell Therapy for ACLF to Advanced Regeneration in First Chinese Stem Cell Outbound Deal

Company Deals

Huadong Medicine Secures Exclusive China Commercialization Rights for Linaprazan Glurate P‑CAB from Sinorda

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.